NCT07088471Completed
Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan
Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan: The CLEAR Study.
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart that occur in heart failure. However, not all patients respond to the drug. Further research is needed to better understand the reasons for this and predict who will benefit most from the drug. Left atrial strain is a relatively new measurement that can be obtained using ultrasound imaging of the heart, and it provides objective information about how one of the heart's four chambers is functioning. The investigators aim to assess the effect of SV therapy on left atrial strain in patients with heart failure. The investigator's objective is to understand whether abnormal left atrial strain or changes in left atrial strain help predict response to SV therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 334 (actual)
- First submitted
- 20 Jul 2025
- Start date
- 1 Nov 2024
- Primary completion date
- 1 May 2025
- Lead sponsor
- Connolly Hospital Blanchardstown
- Diseases
- Heart failure
- NCT number
- NCT07088471
What you commit to
- Study type: Observational
- Participants enrolled: 334
- From 1 Nov 2024 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior mitral valve intervention (left atrial strain assessment unreliable in this cohort)
Other
- Patients not in sinus rhythm at time of echocardiograms (precludes left atrial strain analysis)
- Sub-optimal echocardiographic images to allow measurement of left atrial strain
- Severe mitral regurgitation (left atrial strain assessment unreliable in this cohort)
Who the study is looking for
- Adults diagnosed with heart Failure with reduced ejection fraction (HFrEF), i.e. LVEF ≤40% by Simpson's method on transthoracic echocardiography
- Stable guideline-directed medical therapy prior to sacubitril/valsartan (SV) initiation
- New York Heart Association classes II-III symptom status
- Guideline-directed up-titration of SV therapy to the maximum tolerated dose
- Transthoracic echocardiogram and NT-proBNP prior to SV initiation and at 3 months post commencement of therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Connoly Hospital Blanchardstown Coordinator of this site? Confirm its status | Dublin | Ireland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.